Top 5 Drug Type | Count |
---|---|
Small molecule drug | 12 |
Chemical drugs | 3 |
Synthetic peptide | 3 |
Antibody drug conjugate (ADC) | 1 |
Exosomes | 1 |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. South Korea |
First Approval Date29 Apr 2005 |
Target |
Mechanism PELI1 inhibitors |
Active Org. |
Originator Org.- |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism TGF-β1 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date20 Sep 2024 |
Sponsor / Collaborator |
Start Date02 May 2024 |
Sponsor / Collaborator |
Start Date28 Feb 2023 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
BBT-401 ( PELI1 ) | Colitis, Ulcerative More | Phase 2 |
YH14618 ( TGF-β1 ) | Pain More | Phase 1 |
Compound 4u (Sungkyunkwan University) ( HDAC6 ) | Inflammation More | Preclinical |
Bacillimidazole G | MRSA - Methicillin resistant Staphylococcus aureus infection More | Preclinical |
BVB-808 ( JAK2 ) | Neoplasms More | Preclinical |